Skip to main content
SpringerLink
Log in

Cefotaxime Dosage in Infants and Children

Pharmacokinetic and Clinical Rationale for an Extended Dosage Interval

  • Research Review Article
  • Research Review
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Summary

Cefotaxime is a third generation cephalosporin antimicrobial agent which has received wide acceptance as a first-line antibiotic for many infections in neonates, infants and children. With an average elimination half-life of about 1h, cefotaxime is not considered to be a ‘long half-life cephalosporin’ like ceftriaxone. For this reason, currently accepted dosage regimens for cefotaxime in infants and children employ a dosage of 50 mg/kg every 6h.

Re-examination of the paediatric pharmacokinetic data for cefotaxime and use of simple multiple-dose pharmacokinetic simulation of alternative dosage regimens was performed. From this analysis, regimens administering 75 mg/kg of the drug every 8h or every 12h were projected to produce serum cefotaxime concentrations adequate to effectively kill many of the common pathogens against which the drug is currently indicated for use in children. The clinical utility of these alternative dosage regimens was supported by a review of the medical literature and examination of the clinical results from studies in neonates, infants and children where cefotaxime was administered in 2 to 3 divided doses daily. It would appear, therefore, that increasing the cefotaxime dosage to 75 mg/kg administered at 8h intervals would result in less frequent drug administration which would not be expected to compromise safety and efficacy. Alternative dosage regimens for cefotaxime merit further consideration and clinical evaluation before they become commonly used in paediatric therapeutics.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Andriono T, Susanta I, Makmuri M, Santosa G. Acute mediastinitis. Paediatrica Indonesiana 29: 116–120, 1989

    PubMed  CAS  Google Scholar 

  • Aufrant C, Lambert-Zechovsky N, Aujard Y, Bingin E, Blum C, et al. Cefotaxime and Gram-negative infections in children: effectiveness and tolerance. Nouvelle Presse Medicale 10: 639–646, 1981

    PubMed  CAS  Google Scholar 

  • Badelon O, Bingen E, Sauzeau C, Lambert-Zechovsky N, Ribier A, et al. First line antibiotic treatment in bone and joint sepsis in children. Pathologie Biologie 36: 746–749, 1988

    PubMed  CAS  Google Scholar 

  • Baird-Lambert J, Doyle PE, Thomas D, Cvejic M, Buchanan N. Pharmacokinetics of cefotaxime in neonates. Journal of Antimicrobial Chemotherapy 13: 471–477, 1984

    Article  PubMed  CAS  Google Scholar 

  • Bingen E, Lambert-Zechovsky N, Aujard Y, Blondin G, Mariani P, et al. Beta-lactamase activity in bronchial sputum and treatment failure against penicillin-sensitive bacteria in pulmonary infections. Journal of Antimicrobial Chemotherapy 24: 622–624, 1989

    Article  PubMed  CAS  Google Scholar 

  • Blumer JL, Stern RC, Yamashita TS, Myers CM, Reed MD. Cephalosporin therapeutics in cystic fibrosis. Journal of Pediatrics 108: 854–860, 1986

    Article  PubMed  CAS  Google Scholar 

  • Cho N, Fukunaga K, Kuni K. A study of clinical application of cefotaxime in perinatal period. Japanese Journal of Antibiotics 35: 1855–1876, 1982

    PubMed  CAS  Google Scholar 

  • Crooks J, White LO, Burville LJ, Speidel BD, Reeves DS. Pharmacokinetics of cefotaxime and desacetyl-cefotaxime in neonates. Journal of Antimicrobial Chemotherapy 14 (Suppl. B): 97–101, 1984

    PubMed  Google Scholar 

  • De Louvois J, Mulhall A, Hurley R. The safety and pharmacokinetics of cefotaxime in the treatment of neonates. Pediatric Pharmacology 2: 275–284, 1983

    Google Scholar 

  • Doraiswamy B, Hammerschlag MR, Pringle GF, Du Bouchet L. Ophthalmia neonatorum caused by β-lactamase-producing Neisseria gonorrhoeae. Journal of the American Medical Association 250: 790–791, 1983

    Article  PubMed  CAS  Google Scholar 

  • Feldstein TJ, Uden DL, Larson TA. Cefotaxime for treatment of Gram-negative bacterial meningitis in infants and children. Pediatric Infectious Disease Journal 6: 471–475, 1987

    Article  PubMed  CAS  Google Scholar 

  • Fraise AP, Meeks ACG, Richards JE. Meningitis due to Haemophilus influenzae resistant to ampicillin and chloramphenicol. Archives of Disease in Childhood 61: 1134–1135, 1986

    Article  PubMed  CAS  Google Scholar 

  • Friis H. Antibacterial activity of cefotaxime, desacetylcefotaxime and the combination of the two. Diagnostic Microbiology and Infectious Diseases 12: 67–72, 1989

    Article  CAS  Google Scholar 

  • Garnier JM, Giraud F. Cefotaxime in childhood infections. Nouvelle Presse Medicale 10: 629–633, 1981

    PubMed  CAS  Google Scholar 

  • Gekle D, Rangoonwala R, Seeger K. Clinical and kinetic studies on cefotaxime in the treatment of bacterial infections in children. Infection 8 (Suppl. 4): S509–S512, 1980

    Article  Google Scholar 

  • Gouyon JB, Duez JM, Portier H, Brichon P, Kohli E, et al. The fosfomycin-cefotaxime combination in severe staphylococcal infections in neonates. Presse Medicale 14: 2135–2138, 1985

    CAS  Google Scholar 

  • Haffejee IE. Cefotaxime versus penicillin-chloramphenicol in purulent meningitis: a controlled single-blind clinical trial. Annals of Tropical Paediatrics 8: 225–229, 1988

    PubMed  CAS  Google Scholar 

  • Haffejee IE. A therapeutic trial of cefotaxime versus penicillin-gentamicin for severe infections in children. Journal of Antimicrobial Chemotherapy 14 (Suppl. B): 147–152, 1984

    PubMed  Google Scholar 

  • Hall MA, Ducker DA, Lowes JA, McMichael J, Clarke P, et al. A randomised prospective comparison of cefotaxime versus netilmicin/penicillin for treatment of suspected neonatal sepsis. Drugs 35 (Suppl. 2): 169–177, 1988

    Article  PubMed  Google Scholar 

  • Hall MA, Beech RC, Seal DV. The use of cefotaxime for treating suspected neonatal sepsis: 2 years’ experience. Journal of Hospital Infection 8: 57–63, 1986

    Article  PubMed  CAS  Google Scholar 

  • Hashira S, Koike Y, Fujii R. Fundamental and clinical investigations of cefotaxime in neonates. Japanese Journal of Antibiotics 35: 1737–1748, 1982

    PubMed  CAS  Google Scholar 

  • Helwig H, Schlegel P. Cefotaxime monotherapy in bacterial meningitis of childhood. Monatsschrift für Kinderheilkunde 134: 733–737, 1986

    CAS  Google Scholar 

  • Helwig H, Nelson JD, Grassi C. Cefotaxime in pediatrics. In Nelson & Grassi (Eds) Current chemotherapy of infectious disease: Proceedings of the 11th ICC and 19th ICAAC, pp. 128–129, American Society of Microbiology, Boston, Oct 1–5, 1979

    Google Scholar 

  • Helwig H. Experience with cefotaxime in children. Infection 8 (Suppl. 4): S506–S508, 1980

    Article  Google Scholar 

  • Helwig HF. Cefotaxime in pediatrics. In Abstracts of the 11th ICC and 19th ICAAC, American Society of Microbiology, Boston, Oct 1–5, 1979

    Google Scholar 

  • Hervas JA, Ciria L, Henales V, Lopez P, De La Fuente A, et al. Nonsurgical management of neonatal multiple brain abscesses due to Proteus mirabilis. Helvetica Paediatrica Acta 42: 451–456, 1987

    PubMed  CAS  Google Scholar 

  • Ichioka T, Miyao M. Clinical experience with cefotaxime in bacterial infections of children. Chemotherapy 28 (Suppl. 1): 556–559, 1980

    Google Scholar 

  • Ings RMJ, Fillastre JP, Godin M, Leroy A, Humbert G. The pharmacokinetics of cefotaxime and its metabolites in subjects with normal and impaired renal function. Reviews of Infectious Diseases 4 (Suppl.): S366–373, 1982

    Article  Google Scholar 

  • Iwai N, Sasaki A, Taneda Y, Mizoguchi F, Nakamura H. Study on use of cefotaxime in neonates. Japanese Journal of Antibiotics 35: 1783–1792, 1982

    PubMed  CAS  Google Scholar 

  • Jacobs RF. Cefotaxime treatment of Gram-negative enteric meningitis in infants and children. Drugs 35 (Suppl. 2): 185–189, 1988

    Article  PubMed  Google Scholar 

  • Jacobs RF, Kearns GL. Cefotaxime and desacetylcefotaxime in neonates and children: a review of microbiologic, pharmacokinetic and clinical experience. Diagnostic Microbiology and Infectious Diseases 12: 93–99, 1989

    Article  CAS  Google Scholar 

  • Kafetzis DA, Brater DG, Kanarios J, Sinaniotis CA, Papadatos CJ. Clinical pharmacology of cefotaxime in pediatric patients. Antimicrobial Agents and Chemotherapy 20: 487–490, 1981

    Article  PubMed  CAS  Google Scholar 

  • Kafetzis DA, Brater DG, Kapiki AN, Papas CV, Dellagrammaticas H, et al. Treatment of severe neonatal infections with cefotaxime: efficacy and pharmacokinetics. Journal of Pediatrics 100: 483–489, 1982

    Article  PubMed  CAS  Google Scholar 

  • Kearns GL, Jacobs RF, Thomas BR, Darville TL, Trang JM. Cefotaxime and desacetylcefotaxime pharmacokinetics in very low birth weight neonates. Journal of Pediatrics 114: 461–467, 1989

    Article  PubMed  CAS  Google Scholar 

  • Kearns GL, Reed MD. Clinical pharmacokinetics in infants and children: a reappraisal. Clinical Pharmacokinetics 17 (Suppl. 1): 29–67, 1989

    Article  PubMed  Google Scholar 

  • Lecour H, Seara A, Cordeiro J, Miranda M. Treatment of childhood bacterial meningitis. Infection 17: 343–346, 1989

    Article  PubMed  CAS  Google Scholar 

  • Lolekha S, Poojenapun A. Cefotaxime in serious and antibiotic-resistant infections in children. Journal of the Medical Association of Thailand 67: 392–396, 1984

    PubMed  CAS  Google Scholar 

  • Marget W, Belohradsky B, Roos R. Effect of revised drug schedules with the cephalosporine HR756 on the treatment of severe infections. Abstract A296. In Abstracts of the 18th ICAAC, American Society for Microbiology, Atlanta, October, 1978

    Google Scholar 

  • Marquardt DW. An algorithm for least-squares estimation of nonlinear parameters. Journal of the Society of Industrial and Applied Mathematics 11: 431–441, 1963

    Article  Google Scholar 

  • McCracken GH Jr, Threlkeld NE, Thomas ML. Pharmacokinetics of cefotaxime in newborn infants. Antimicrobial Agents and Chemotherapy 21: 683–684, 1982

    Article  PubMed  CAS  Google Scholar 

  • Morselli PL. Clinical pharmacology of the perinatal period and early infancy. Clinical Pharmacokinetics 17 (Suppl. 1): 13–28, 1989

    Article  PubMed  Google Scholar 

  • Nakazawa S, Sato H, Suzuki H, Iwasaki A, Niino K, et al. Cefotaxime in pediatrics: basic and clinical studies. Chemotherapy 28 (Suppl. 1): 468–478, 1980

    Google Scholar 

  • Nanri S, Akita H, Jozaki K, Iwata S, Twasaki Y, et al. Fundamental and clinical studies of cefotaxime in neonates and immature infants. Japanese Journal of Antibiotics 35: 1749–1760, 1982

    PubMed  CAS  Google Scholar 

  • Nishibayashi Y, Hamawaki M, Ozaki H, Kitamura I. The therapeutic effects of cefotaxime on various infectious diseases in children. Chemotherapy 28 (Suppl. 1): 560–569, 1980

    Google Scholar 

  • Odio CM, Faingezicht I, Mohs E, Salas JL, McCracken GH. Cefotaxime (CTX) versus conventional therapy for bacterial meningitis in infants and children. Abstract 132. In Abstracts of the 24th ICAAC, American Society for Microbiology, Washington, DC, October 8–10, 1984

    Google Scholar 

  • Ohkawa M, Okasho A, Motoi I, Togunaga S, Shoda R, et al. Elimination kinetics of cefotaxime and desacetylcefotaxime in patients with renal insufficiency and during hemodialysis. Chemotherapy 29: 4–12, 1983

    Article  PubMed  CAS  Google Scholar 

  • Oran O, Yurdakok M, Tekinalp G, Kanra G. Cefotaxime and amikacin combination in the treatment of salmonella infection in premature infants. Turkish Journal of Pediatrics 30: 247–252, 1988

    Google Scholar 

  • Papadatos CJ, Kafetzis DA, Kanarios J. Cefotaxime in the treatment of severe paediatric infections. Journal of Antimicrobial Chemotherapy 6 (Suppl. A): 243–248, 1980

    PubMed  Google Scholar 

  • Peters HH, Tillmann W, Schroeter W. Clinical experience with cefotaxime in anti-infection therapy of children treated with cytotoxic drugs. Infection 8(Supp. 4): S513–S515, 1980

    Article  Google Scholar 

  • Pils P, Schmidt P, Zazgornik J, Graninger W, Kopsa H, et al. Azlocillin and HR 756 in urosepsis and urinary tract infections with multiresistant Pseudomonas and Proteus morganii. Deutsche Medizinische Wochenschrift 104: 66–67, 1979

    PubMed  CAS  Google Scholar 

  • Porras-Ramirez G, Mendez Calderon E, Garcia Fernandeaz J, Animas Astorga S. Clinical trial of cefotaxime in severe pediatric infections. Investagación Medica Internacional 9: 51–61, 1982

    Google Scholar 

  • Reynolds V, Oates jk, Newsom SWB. Prepubertal gonococcal vulvovaginitis: a penicillin-resistant infection treated with cefotaxime. Lancet 2: 206–207, 1979

    Article  PubMed  CAS  Google Scholar 

  • Roos R, Marget W, Trujillo H, Kafetzis DA, Papadatos CJ, et al. Multicenter study on cefotaxime in meningitis and septicemia in children: clinica;l results, serum pharmacokinetics and concentrations in cerebrospinal fluid. Infection 8 (Suppl. 4): S501–S505, 1980

    Article  Google Scholar 

  • Rosch W, Welte WA, Clinical experiences with cefotaxim in pediatric surgery. Medizinische Welt 40: 149–153, 1989

    Google Scholar 

  • Rusconi F, Rancilio L, Cerri MA, Parizzi F, Pietrogrande MC, et al. Cefotaxime in the treatment of severe bacterial pneumonia in paediatric patients. Drugs 35 (Suppl. 2): 203–204, 1988

    Article  PubMed  Google Scholar 

  • Scheifele DW, Ginter GL, Olsen E, Fussell S, Pendray M. Comparison of two antibiotic regimens for neonatal necrotizing enterocolitis. Journal of Antimicrobial Chemotherapy 20: 421–429, 1987

    Article  PubMed  CAS  Google Scholar 

  • Sow A. Cefotaxime treatment of meningitis in children. Journal of Antimicrobial Chemotherapy 14 (Suppl. B): 191–194, 1984

    PubMed  Google Scholar 

  • Steele RW. Ceftriaxone: increasing the half-life and activity of the third generation cephalosporins. Pediatric Infectious Diseases Journal 4: 188–191, 1985

    Article  CAS  Google Scholar 

  • Steele RW, Eyre LB, Bradsher RW, et al. Pharmacokinetics of ceftriaxone in pediatric patients with meningitis. Antimicrobial Agents and Chemotherapy 23: 191–194, 1983

    Article  PubMed  CAS  Google Scholar 

  • Steele RW, Kearns GL. Antimicrobial therapy for pediatric patients. Pediatric Clinics of North America 36: 1321–1349, 1989

    PubMed  CAS  Google Scholar 

  • Stevens DL, Bergstrom R, Gibbons A. Synergistic interaction of cefotaxime and its metabolite desacetylcefotaxime demonstrated by drug-impregnated disks. Diagnostic Microbiology and Infectious Diseases 12: 73–80, 1989

    Article  CAS  Google Scholar 

  • Toyonaga Y, Kurosu Y, Sugita M, Hori M. Basic and clinical studies on use of cefotaxime in neonates. Japanese Journal of Antibiotics 35: 1767–1782, 1982

    PubMed  CAS  Google Scholar 

  • Trang JM, Jacobs RF, Kearns GL, Brown AL, Wells TG, et al. Cefotaxime and desacetylcefotaxime pharmacokinetics in infants and children with meningitis. Antimicrobial Agents and Chemotherapy 28: 791–795, 1985

    Article  PubMed  CAS  Google Scholar 

  • Varghese M, Khan AJ, Kumar K, Schaeffer HA, Pierro M, et al. Evaluation of cefotaxime in bacterial infections. Clinical Pediatrics 23: 220–222, 1984

    Article  PubMed  CAS  Google Scholar 

  • Vogelman B, Craig WA. Kinetics of antimicrobial activity. Journal of Pediatrics 108: 835–840, 1986

    Article  PubMed  CAS  Google Scholar 

  • von Loewenich V, Miething R, Uihlein M, Knothe M, Greipel-Zamorski M. Cefotaxime and deacetyl-cefotaxime in cerebrospinal fluid of newborn and premature infants. Pediatrie und Padologie 18: 361–366, 1983

    Google Scholar 

  • Weber SA, Tuohy P. Bacteroides fragilis meningitis in a premature infant successfully treated with metronidazole. Pediatric Infectious Disease Journal 7: 886–887, 1988

    Google Scholar 

  • Wise R, Wright N, Wills PJ. Pharmacology of cefotaxime and its desacetyl metabolite in renal and hepatic disease. Antimicrobial Agents and Chemotherapy 19: 526–531, 1981

    Article  PubMed  CAS  Google Scholar 

  • Yamaoka K, Nakagawa T, Uno T. Application of Akaike’s information criterion (AIC) in the evaluation of linear pharmacokinetic equations. Journal of Pharmacokinetics and Biopharmaceutics 6: 165175, 1978

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pediatrics, University of Arkansas for Medical Sciences, USA

    Gregory L. Kearns (Associate Professor of Pediatrics, Chief), Ronald A. Young & Richard F. Jacobs

  2. Divisions of Pediatric Clinical Pharmacology and of Infectious Disease and the Department of Pharmacy, Arkansas Children’s Hospital, Little Rock, Arkansas, USA

    Gregory L. Kearns (Associate Professor of Pediatrics, Chief), Ronald A. Young & Richard F. Jacobs

Authors
  1. Gregory L. Kearns
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ronald A. Young
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Richard F. Jacobs
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kearns, G.L., Young, R.A. & Jacobs, R.F. Cefotaxime Dosage in Infants and Children. Clin. Pharmacokinet. 22, 284–297 (1992). https://doi.org/10.2165/00003088-199222040-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-199222040-00004

Keywords

Search

Navigation